• July 2, 2007

Lev Pharmaceuticals, Inc. is finalizing its marketing and sales management team for the launch of its lead product candidate, C1-esterase inhibitor, to be marketed as Cinryze, for the treatment of hereditary angioedema. FDA approval is pending.

Joe Truitt, VP/sales and marketing, says key members include Susanne Heinzinger, director of marketing, and Mark Collins, national sales director.

Heinzinger was a corporate account director/reimbursement for OraPharma, a Johnson & Johnson company, where she developed and implemented marketing programs for the company's flagship product, Arestin. Prior to Johnson & Johnson, Heinzinger was product manager at TAP Pharmaceuticals, where she worked on the commercial launch for Lupron Depot.

Collins previously was at Guidant, a Boston Scientific company, and before that was at TAP Pharmaceuticals, where he worked on the launch of Prevacid, a leading heartburn relief medication.--Tanya Irwin